Inulin-type fructans are fermentable plant fibers from chicory root used as oral dietary supplements to support gut bacteria, metabolism, bowel regularity, and longevity. Clinical trials show strong evidence for lowering elevated blood sugar, insulin resistance, cholesterol, triglycerides, and constipation, plus moderate evidence for improving memory in older adults. Gradual oral dose increases using longer-chain chicory inulin minimize flatulence, bloating, loose stools, and high-dose liver stress. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Fasting Plasma Glucose | 3.9–5.5 mmol/L (70–99 mg/dL) (standard reference range) | Expected to change: tracks glycemic response to ITF-induced GLP-1 and SCFA signaling (paired with fasting insulin to compute HOMA-IR). |
| HbA1c | 4.0–5.6% (standard reference range) | Expected to change: quantifies 8–12-week integrated blood glucose reduction. |
| LDL-C & Triglycerides | LDL-C <3.4 mmol/L (<130 mg/dL); Triglycerides <1.7 mmol/L (<150 mg/dL) (standard reference range) | Expected to change: evaluates hepatic lipid-synthesis inhibition and bile acid excretion. |
| Serum ALT | 10–40 U/L in males; 7–35 U/L in females (standard reference range) | Safety check: detects high-dose fiber-induced hepatocellular stress. |
| Serum Magnesium | 0.70–1.00 mmol/L (1.70–2.43 mg/dL) (standard reference range) | Expected to change: verifies reversal of PPI-induced hypomagnesemia or enhanced mineral uptake. |
| Fecal Calprotectin | <50 µg/g stool (standard reference range) | Safety check: rules out active mucosal inflammation before or during β-fructan use. |
Cadence: Baseline; subjective gastrointestinal tolerance and weekly stool frequency at 1 week and 4 weeks; serum magnesium at 2–4 weeks (in chronic PPI users); repeat cardiometabolic, mineral, and hepatic safety biomarkers at 8–12 weeks and every 6–12 months thereafter.